Article
Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody.
Blood - 15 Aug 2004
Li Yiwen, Li Hongli, Wang Mei-Nai, Lu Dan, Bassi Rajiv, Wu Yan, Zhang Haifan, Balderes Paul, Ludwig Dale L, Pytowski Bronislaw, Kussie Paul, Piloto Obdulio, Small Donald, Bohlen Peter, Witte Larry, Zhu Zhenping, Hicklin Daniel J
Abstract excerpt
FMS-like tyrosine kinase 3 (FLT3), a class III receptor tyrosine kinase, is expressed at high levels in the blasts of approximately 90% of patients with acute myelogenous leukemia (AML). Internal tandem duplications (ITDs) in the juxtamembrane domain and point mutations in the kinase domain of FLT3 are found in approximately 37% of AML patients and are associated with a poor prognosis. We report here the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.